Monte Rosa Therapeutics, Inc. Investing Cash Flow
Monte Rosa Therapeutics, Inc. (GLUE) reported Investing Cash Flow of -$289.86 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-06
- Monte Rosa Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was -$28.86M, a 213.96% decline year-over-year.
- Monte Rosa Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was -$261.00M.
- Monte Rosa Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was -$65.07M.
- Monte Rosa Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $38.14M, a 1.03% increase year-over-year.
- Monte Rosa Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2025 was -$101.83M.
- Monte Rosa Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2024 was -$44.45M, a 150.06% decline from fiscal 2023.
- Monte Rosa Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2023 was $88.80M.
- Monte Rosa Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2022 was -$219.22M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$28.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$289.86M 10-Q · filed 2026-08-06 | -$354.92M derived: sum of 3 quarters · filed 2026-08-06 | -$316.79M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$261.00M 10-Q · filed 2026-05-07 | -$326.06M derived: sum of 2 quarters · filed 2026-05-07 | -$287.93M derived: sum of 3 quarters · filed 2026-05-07 | -$262.60M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$65.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$26.93M derived: sum of 2 quarters · filed 2026-03-17 | -$1.60M derived: sum of 3 quarters · filed 2026-08-06 | -$101.83M 10-K · filed 2026-03-17 |
| 2025-09-30 | $38.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $63.46M derived: sum of 2 quarters · filed 2026-08-06 | -$36.77M 10-Q · filed 2025-11-06 | -$67.66M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $25.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$74.91M 10-Q · filed 2026-08-06 | -$105.80M derived: sum of 3 quarters · filed 2026-08-06 | -$68.05M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$100.23M 10-Q · filed 2026-05-07 | -$131.13M derived: sum of 2 quarters · filed 2026-05-07 | -$93.38M derived: sum of 3 quarters · filed 2026-05-07 | -$154.53M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$30.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $6.85M derived: sum of 2 quarters · filed 2026-03-17 | -$54.30M derived: sum of 3 quarters · filed 2026-03-17 | -$44.45M 10-K · filed 2026-03-17 |
| 2024-09-30 | $37.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$23.41M derived: sum of 2 quarters · filed 2025-11-06 | -$13.56M 10-Q · filed 2025-11-06 | $741.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$61.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$51.30M 10-Q · filed 2025-08-07 | -$37.01M derived: sum of 3 quarters · filed 2025-08-07 | -$1.38M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $9.85M 10-Q · filed 2025-05-08 | $24.15M derived: sum of 2 quarters · filed 2025-05-08 | $59.78M derived: sum of 3 quarters · filed 2025-05-08 | $78.33M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $14.30M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $49.92M derived: sum of 2 quarters · filed 2025-03-20 | $68.47M derived: sum of 3 quarters · filed 2025-03-20 | $88.80M 10-K · filed 2025-03-20 |
| 2023-09-30 | $35.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $54.18M derived: sum of 2 quarters · filed 2024-11-07 | $74.50M 10-Q · filed 2024-11-07 | $20.57M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $18.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $38.88M 10-Q · filed 2024-08-08 | -$15.06M derived: sum of 3 quarters · filed 2024-08-08 | $14.43M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $20.33M 10-Q · filed 2024-05-09 | -$33.61M derived: sum of 2 quarters · filed 2024-05-09 | -$4.12M derived: sum of 3 quarters · filed 2024-05-09 | -$18.37M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$53.94M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$24.45M derived: sum of 2 quarters · filed 2024-03-14 | -$38.70M derived: sum of 3 quarters · filed 2024-03-14 | -$219.22M 10-K · filed 2024-03-14 |
| 2022-09-30 | $29.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $15.24M derived: sum of 2 quarters · filed 2023-11-09 | -$165.28M 10-Q · filed 2023-11-09 | -$168.33M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$14.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$194.77M 10-Q · filed 2023-08-10 | -$197.82M derived: sum of 3 quarters · filed 2023-08-10 | -$199.50M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$180.52M 10-Q · filed 2023-05-11 | -$183.57M derived: sum of 2 quarters · filed 2023-05-11 | -$185.25M derived: sum of 3 quarters · filed 2023-05-11 | -$187.96M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$3.05M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | -$4.74M derived: sum of 2 quarters · filed 2023-03-16 | -$7.44M derived: sum of 3 quarters · filed 2023-03-16 | -$9.65M 10-K · filed 2023-03-16 |
| 2021-09-30 | -$1.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$4.39M derived: sum of 2 quarters · filed 2022-11-10 | -$6.61M 10-Q · filed 2022-11-10 | -$7.79M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$2.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$4.92M 10-Q · filed 2022-08-11 | -$6.10M derived: sum of 3 quarters · filed 2022-08-11 | -$7.03M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$2.22M 10-Q · filed 2022-05-11 | -$3.40M derived: sum of 2 quarters · filed 2022-05-11 | -$4.33M derived: sum of 3 quarters · filed 2022-05-11 | |
| 2020-12-31 | -$1.19M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | -$2.12M derived: sum of 2 quarters · filed 2022-03-29 | -$3.39M 10-K · filed 2022-03-29 | |
| 2020-09-30 | -$930.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$2.20M 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | -$1.27M 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |